Clinical trial
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2…
NCT00039026 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00039026 |
|---|---|
| Title | Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea |
| Official title | A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With a Sulfonylurea Alone |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Non-Insulin-Dependent |
| Intervention type | Drug |
| Interventions | AC2993, Placebo |
| Enrollment | 377 |
| Start date | Feb 1, 2002 |
| Primary completion | Aug 1, 2003 |
| Completion | Aug 1, 2003 |
| First posted | Jun 10, 2002 |
| Last update posted | Feb 24, 2015 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: